Theragnostics Ltd: Developing New Radiotherapies Targeted To PARP
Prostate Cancer Is One Of The Initial Targets For Theragnostics' Technology
Emerging Company Profile: The transatlantic radiopharmaceuticals start-up Theragnostics Ltd. is developing radiotherapeutics and radiodiagnostics for prostate and other cancers.
You may also be interested in...
Advanced Accelerator Applications is ramping up the launch of the first-in-class peptide receptor radionuclide therapy (PRRT), but Novartis has much broader ambitions for the radiopharmaceutical platform. AAA President Susanne Schaffert talked to Scrip about the growth strategy.
Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.